A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, Myeloma, 17p-, rea 14q32 with Reflexes
Test Code92497
CPT Codes
<br /> 88271 (x4), 88275 (x2) for the FISH, Myeloma, 17p-, rea 14q32 component<br /> 88271 (x7), 88275 (x3) for the FISH, Myeloma, Risk Assessment Panel component
Includes
FISH, Myeloma, 17p-, rea 14q32 and FISH, Myeloma, Risk Assessment Panel
When the result for IGH rearrangement is positive during initial FISH analysis, the IGH Panel (MAFB, MAF, FGFR3, CCND1) will be performed at an additional charge (CPT code(s): 88271 (x8), 88275 (x4)).
This allows identification of high risk t(14;16) and t(14;20), intermediate risk t(4;14), and standard risk t(11;14).
Please note: Partial reports are issued when the sample is insufficient to perform all components of the FISH panel.
When the result for IGH rearrangement is positive during initial FISH analysis, the IGH Panel (MAFB, MAF, FGFR3, CCND1) will be performed at an additional charge (CPT code(s): 88271 (x8), 88275 (x4)).
This allows identification of high risk t(14;16) and t(14;20), intermediate risk t(4;14), and standard risk t(11;14).
Please note: Partial reports are issued when the sample is insufficient to perform all components of the FISH panel.
Preferred Specimen
3 mL bone marrow collected in a sodium heparin (green-top), (royal blue-top), or (lead-free tan-top) tube
Minimum Volume
1 mL
Instructions
1-3 mL bone marrow collected in a sodium heparin tube
Transport Temperature
Room temperature
Specimen Stability
Specimen viability decreases during transit. Send specimen to testing lab for viability determination. Do not freeze. Do not reject.
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 8 days
Clinical Significance
Plasma cell myeloma (PCM) is characterized by the proliferation of malignant monoclonal plasma cells in the bone marrow. Initial FISH testing is performed to detect high risk rearrangements of IGH (14q32) and deletion of TP53 (17p13.1). The prognostic panel also includes probes to detect gains of 1q and monosomy or deletion 13q associated with less favorable outcome and gains of chromosome 9, 11, and 15 associated with more favorable outcome.